DIGIPREDICT — predicting asthma attacks days before they happen

DIGIPREDICT is designed to use everyday smartwatch data to spot the early signature of an asthma attack, days in advance. The goal: fewer hospitalisations, and more good days.

This site needs JavaScript for the full interactive experience. Choose the version that fits you:

For patients & whānau — plain-language information, and how to take part in the SENSAI trial.
For investors & partners — the science, the evidence, and partnership opportunities.

Contact: hello@digipredict.io

DIGIPREDICT is under clinical evaluation (the SENSAI trial, 2026–2027) and is not approved for clinical use or available for supply.

Get Involved arrow_forward Learn More

See it in action

How it works

A short explainer on how DIGIPREDICT is designed to work.

Email Us arrow_forward